Spots Global Cancer Trial Database for metastatic head and neck squamous cell carcinoma

Every month we try and update this database with for metastatic head and neck squamous cell carcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck	NCT05172258	Head and Neck S... Metastatic Head... Metastatic Hypo... Metastatic Lary... Metastatic Oral... Metastatic Orop... Recurrent Head ... Recurrent Hypop... Recurrent Laryn... Recurrent Oral ... Recurrent Oroph... Stage IV Hypoph... Stage IV Laryng... Stage IV Lip an... Stage IV Oropha...	Biopsy Biospecimen Col... Computed Tomogr... Ipatasertib Pembrolizumab	18 Years -	National Cancer Institute (NCI)
Fluciclovine F18 PET/CT in Identifying the Origin of Head and Neck Squamous Cell Carcinoma in Patients With Metastatic Cervical Nodal Disease	NCT03868020	Metastatic Head... Metastatic Squa...	Computed Tomogr... Fluciclovine F1... Positron Emissi...	18 Years -	M.D. Anderson Cancer Center
Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies	NCT03590054	Stage III Cutan... Stage IV Cutane... Locally Advance... Locally Advance... Metastatic Head... Metastatic Mali... Metastatic Mela... Metastatic Urot... Non-Small Cell ... Stage IB Lung C... Stage III Cutan... Stage III Lung ... Stage III Urete... Stage IIIA Lung... Stage IIIB Lung... Stage IIIC Lung... Stage IV Cutane... Stage IV Lung C... Stage IV Ureter... Stage IVA Lung ... Stage IVB Lung ...	Abexinostat Pembrolizumab	18 Years -	University of California, San Francisco
Olaparib in Combination With Pembrolizumab and Carboplatin as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma	NCT04643379	Recurrent Head ... Metastatic Head...	Olaparib Pembrolizumab Carboplatin Peripheral bloo...	18 Years -	Washington University School of Medicine
Losartan, Pembrolizumab and Stereotactic Body Radiation Therapy for the Treatment of Patients With Locally Recurrent, Refractory or Oligometastatic Head and Neck Squamous Cell Carcinoma	NCT06211335	Locally Recurre... Metastatic Head... Refractory Head...	Losartan Pembrolizumab Stereotactic Bo...	18 Years -	University of California, Davis
Olaparib in Combination With Pembrolizumab and Carboplatin as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma	NCT04643379	Recurrent Head ... Metastatic Head...	Olaparib Pembrolizumab Carboplatin Peripheral bloo...	18 Years -	Washington University School of Medicine
Phase II Trial of Pembrolizumab in Recurrent or Metastatic HNSCC	NCT03813836	Metastatic Head... Recurrent Head ...	Pembrolizumab	18 Years -	University College, London
Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery	NCT01468896	Metastatic Head... Recurrent Head ... Unresectable He...	Cetuximab Edodekin alfa Laboratory Biom...	18 Years -	National Cancer Institute (NCI)
Avelumab, Cetuximab, and Palbociclib in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma	NCT03498378	Head and Neck S...	Avelumab Palbociclib Cetuximab	18 Years -	University of California, San Diego
Sorafenib in Combination With Carboplatin and Paclitaxel in Treating Participants With Metastatic or Recurrent Head and Neck Squamous Cell Cancer	NCT00494182	Metastatic Head... Metastatic Squa... Metastatic Squa... Metastatic Squa... Metastatic Squa... Recurrent Head ... Recurrent Hypop... Recurrent Laryn... Recurrent Oral ... Recurrent Oroph...	Carboplatin Paclitaxel Sorafenib	18 Years -	M.D. Anderson Cancer Center
INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma	NCT05359692	Metastatic Head... Advanced Malign... Recurrent Head ...	INCAGN01876 retifanlimab	18 Years - 99 Years	Incyte Corporation
Optimizing Antitumor Immunity Using Plasmid Electroporation, Pembrolizumab, and Epacadostat	NCT03823131	Metastatic Head... Recurrent Head ... Unresectable He...	ImmunoPulse Epacadostat Pembrolizumab CORVax Tavokinogene te...	18 Years -	University of California, San Francisco
Standard and Delayed FDG PET/CT After Chemoradiation Therapy in Assessing Patients With Metastatic Head and Neck Squamous Cell Cancer	NCT03575949	Metastatic Head... Metastatic Mali...	Computed Tomogr... Fludeoxyglucose... Positron Emissi...	18 Years -	M.D. Anderson Cancer Center
Losartan, Pembrolizumab and Stereotactic Body Radiation Therapy for the Treatment of Patients With Locally Recurrent, Refractory or Oligometastatic Head and Neck Squamous Cell Carcinoma	NCT06211335	Locally Recurre... Metastatic Head... Refractory Head...	Losartan Pembrolizumab Stereotactic Bo...	18 Years -	University of California, Davis
Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program	NCT06265285	Advanced Esopha... Advanced Renal ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Esophageal Carc... Gastroesophagea... Hepatocellular ... Locally Advance... Lung Non-Small ... Malignant Solid... Metastatic Colo... Metastatic Cuta... Metastatic Esop... Metastatic Head... Metastatic Urot... Recurrent Esoph... Recurrent Head ... Renal Cell Carc... Stage III Renal... Stage IV Colore... Stage IV Cutane... Stage IV Renal ... Unresectable Cu... Unresectable Es... Urothelial Carc...	Home Health Enc... Nivolumab Patient Monitor... Questionnaire A...	18 Years -	Mayo Clinic
Durvalumab, Tremelimumab and Hypofractionated Radiation Therapy in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma	NCT03522584	Metastatic Head... Recurrent Head ...	Durvalumab Laboratory Biom... Stereotactic Bo... Tremelimumab Hypofractionate...	18 Years -	University of Washington
Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors	NCT04007744	Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Locally Advance... Locally Advance... Locally Advance... Metastatic Gast... Metastatic Gast... Metastatic Head... Metastatic Lung... Metastatic Mali... Metastatic Mela... Metastatic Urot... Recurrent Head ... Refractory Lung... Stage IV Cutane... Stage IV Lung C... Unresectable Ma... Unresectable Me...	Pembrolizumab Sonidegib	18 Years -	Mayo Clinic
Phase II Trial of Pembrolizumab in Recurrent or Metastatic HNSCC	NCT03813836	Metastatic Head... Recurrent Head ...	Pembrolizumab	18 Years -	University College, London
Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck	NCT04862650	Clinical Stage ... Metastatic Head... Metastatic Hypo... Metastatic Lary... Metastatic Oral... Metastatic Orop... Pathologic Stag... Recurrent Head ... Recurrent Hypop... Recurrent Laryn... Recurrent Oral ... Recurrent Oroph... Squamous Cell C... Stage IV Hypoph... Stage IV Laryng... Stage IV Lip an... Stage IVA Hypop... Stage IVA Laryn... Stage IVA Lip a... Stage IVB Hypop... Stage IVB Laryn... Stage IVB Lip a... Stage IVC Hypop... Stage IVC Laryn... Stage IVC Lip a...	Carboplatin Cemiplimab Paclitaxel	18 Years -	Ohio State University Comprehensive Cancer Center
Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck	NCT05172258	Head and Neck S... Metastatic Head... Metastatic Hypo... Metastatic Lary... Metastatic Oral... Metastatic Orop... Recurrent Head ... Recurrent Hypop... Recurrent Laryn... Recurrent Oral ... Recurrent Oroph... Stage IV Hypoph... Stage IV Laryng... Stage IV Lip an... Stage IV Oropha...	Biopsy Biospecimen Col... Computed Tomogr... Ipatasertib Pembrolizumab	18 Years -	National Cancer Institute (NCI)
(89Zr Panitumumab) With PET/CT for Diagnosing Metastases in Patients With Head and Neck Squamous Cell Carcinoma	NCT05747625	Head and Neck S... Metastatic Head... Stage IV Cutane...	Panitumumab Zirconium Zr 89... Positron Emissi... Computed Tomogr... Electronic Heal...	19 Years -	Vanderbilt-Ingram Cancer Center
Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck	NCT04862650	Clinical Stage ... Metastatic Head... Metastatic Hypo... Metastatic Lary... Metastatic Oral... Metastatic Orop... Pathologic Stag... Recurrent Head ... Recurrent Hypop... Recurrent Laryn... Recurrent Oral ... Recurrent Oroph... Squamous Cell C... Stage IV Hypoph... Stage IV Laryng... Stage IV Lip an... Stage IVA Hypop... Stage IVA Laryn... Stage IVA Lip a... Stage IVB Hypop... Stage IVB Laryn... Stage IVB Lip a... Stage IVC Hypop... Stage IVC Laryn... Stage IVC Lip a...	Carboplatin Cemiplimab Paclitaxel	18 Years -	Ohio State University Comprehensive Cancer Center
Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery	NCT01468896	Metastatic Head... Recurrent Head ... Unresectable He...	Cetuximab Edodekin alfa Laboratory Biom...	18 Years -	National Cancer Institute (NCI)
Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers	NCT05063552	Clinical Stage ... Metastatic Head... Metastatic Hypo... Metastatic Lary... Metastatic Lip ... Metastatic Nasa... Metastatic Naso... Metastatic Phar... Metastatic Sino... Recurrent Head ... Recurrent Hypop... Recurrent Laryn... Recurrent Lip a... Recurrent Nasop... Recurrent Phary... Recurrent Sinon... Stage IV Hypoph... Stage IV Laryng... Stage IV Lip an... Stage IV Nasoph... Stage IV Oropha... Stage IV Sinona...	Atezolizumab Bevacizumab Biospecimen Col... Carboplatin Cetuximab Cisplatin Computed Tomogr... Docetaxel Echocardiograph... Magnetic Resona... Positron Emissi...	18 Years -	National Cancer Institute (NCI)
INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma	NCT05359692	Metastatic Head... Advanced Malign... Recurrent Head ...	INCAGN01876 retifanlimab	18 Years - 99 Years	Incyte Corporation
Camrelizumab in Combination With Chemotherapy or Apatinib Mesylate as First-Line Treatment for R/M HNSCC	NCT05156970	Recurrent Head ... Metastatic Head...	Camrelizumab Cisplatin Docetaxel Apatinib Mesyla... Carboplatin	18 Years - 75 Years	Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors	NCT04007744	Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Locally Advance... Locally Advance... Locally Advance... Metastatic Gast... Metastatic Gast... Metastatic Head... Metastatic Lung... Metastatic Mali... Metastatic Mela... Metastatic Urot... Recurrent Head ... Refractory Lung... Stage IV Cutane... Stage IV Lung C... Unresectable Ma... Unresectable Me...	Pembrolizumab Sonidegib	18 Years -	Mayo Clinic
Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program	NCT06265285	Advanced Esopha... Advanced Renal ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Esophageal Carc... Gastroesophagea... Hepatocellular ... Locally Advance... Lung Non-Small ... Malignant Solid... Metastatic Colo... Metastatic Cuta... Metastatic Esop... Metastatic Head... Metastatic Urot... Recurrent Esoph... Recurrent Head ... Renal Cell Carc... Stage III Renal... Stage IV Colore... Stage IV Cutane... Stage IV Renal ... Unresectable Cu... Unresectable Es... Urothelial Carc...	Home Health Enc... Nivolumab Patient Monitor... Questionnaire A...	18 Years -	Mayo Clinic
Camrelizumab in Combination With Chemotherapy or Apatinib Mesylate as First-Line Treatment for R/M HNSCC	NCT05156970	Recurrent Head ... Metastatic Head...	Camrelizumab Cisplatin Docetaxel Apatinib Mesyla... Carboplatin	18 Years - 75 Years	Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 Plus Tilsotolimod and Other Therapy Combinations in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma	NCT04196283	Advanced Solid ...	ABBV-368 Tilsotolimod Nab-paclitaxel ABBV-181	18 Years -	AbbVie

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: